Clinical Trial Update: Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Aurexis in cystic fibrosis patients chronically colonized with Staphylococcus aureus in the lungs completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Staphylococcus Aureus Infection

Drugs mentioned

• Aurexis

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Staphylococcus Aureus | Phase 2 | Status: COMPLETED